Tilpasning av DynaCellect magnetseparasjons-instrumentet for Dynabeads mRNA arbeidsflyten

Offentlig prosjektsammendrag

Thermo Fisher Scientific Norway is launching a project to automate the production of mRNA-based drugs, like those used in COVID-19 vaccines. The goal is to adapt existing technology to create a fully automated, compliant system for manufacturing small doses of mRNA therapeutics, which are essential for treating rare diseases and personalized medicine. Current methods are often manual and not up to regulatory standards. The project will begin with a study to identify necessary changes to the DynaCellect instrument, designed by Thermo Scientific Norway. If successful, it will develop new workflows and software to ensure high-quality, efficient, and reliable mRNA production. This initiative aims to fill a critical market gap and support the growing field of mRNA therapeutics.